4 completed. 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 4 |
Follow Glycopyrronium Bromide: new trials by email Literature Review of Glycopyrronium Bromide trials Research Report on Glycopyrronium Bromide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD Beclomethasone Dipropionate, Glycopyrronium Bromide, Formoterol Fumarate - COPD, COPD Exacerbation | Phase 3 | Completed | Chiesi Farmaceutici S.p.A. | 3406 | 2022-04-27 | 2026-09-21 |
| Efficacy, Safety and Tolerability of the Co-administration of NVA237 Plus Indacaterol Once Daily Versus Indacaterol Once Daily in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) NVA237 50 µg and indacaterol 150 µg, Placebo to NVA237 and indacaterol 150 µg - Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | Completed | Novartis Pharmaceuticals | 449 | 2012-05-01 | 2014-11-14 |
| A Study to Assess the Safety, Tolerability and Efficacy of NVA237 Versus Placebo Glycopyrronium bromide, Placebo - Chronic Obstructive Pulmonary Disease | Phase 3 | Completed | Novartis | 1324 | 2009-10-01 | 2012-04-12 |
| 1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD) Glycopyrronium bromide, Placebo to glycopyrronium bromide, Tiotropium - Chronic Obstructive Pulmonary Disease | Phase 3 | Completed | Novartis | 1066 | 2009-06-01 | 2012-08-17 |
Pulmonary Disease, Chronic Obstructive (4)
Novartis (2) · Chiesi Farmaceutici S.p.A. (1) · Novartis Pharmaceuticals (1)
Canada (3) · Hungary (3) · Russia (3) · United States (3) · Argentina (2) · Bulgaria (2) · Mexico (2) · Netherlands (2) · Poland (2) · Romania (2) · South Korea (2) · Spain (2) · Turkey (Türkiye) (2) · Australia (1) · Belgium (1)
Thomas Siler, MD (1)
PMID 24156566, PMID 22151296, PMID 23060624, PMID 24596459
2008 (1), 2009 (1), 2023 (1)